Diphtheria-Tetanus-acellular Pertussis Vaccines Clinical Trial
Official title:
Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea
The purpose of this study is to collect safety information from pre-adolescents, adolescents and adults after Boostrix vaccination is administered according to the approved prescribing information in Korea.
Protocol amendment 3 rationale was as follows:
- Age for analysis set is specified.
- Subjects with pregnancy will be analyzed by their pregnancy status before/after
vaccination.
- Pregnancy notifications must be done within 2 weeks
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04082299 -
Immune Response followingTdap Vaccine in Pregnancy
|
||
| Completed |
NCT02377349 -
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
|
Phase 4 | |
| Completed |
NCT02569879 -
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.
|
||
| Completed |
NCT00548171 -
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058
|
Phase 4 | |
| Completed |
NCT01568060 -
Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea
|
||
| Completed |
NCT03311659 -
Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects
|
Phase 3 | |
| Completed |
NCT00835237 -
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
|
Phase 3 |